Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Dlx1/2 mice have abnormal enteric nervous system function
Christina M. Wright, James P. Garifallou, Sabine Schneider, Heather L. Mentch, Deepika R. Kothakapa, Beth A. Maguire, Robert O. Heuckeroth
Christina M. Wright, James P. Garifallou, Sabine Schneider, Heather L. Mentch, Deepika R. Kothakapa, Beth A. Maguire, Robert O. Heuckeroth
View: Text | PDF
Research Article Development Neuroscience

Dlx1/2 mice have abnormal enteric nervous system function

  • Text
  • PDF
Abstract

Decades ago, investigators reported that mice lacking DLX1 and DLX2, transcription factors expressed in the enteric nervous system (ENS), die with possible bowel motility problems. These problems were never fully elucidated. We found that mice lacking DLX1 and DLX2 (Dlx1/2–/– mice) had slower small bowel transit and reduced or absent neurally mediated contraction complexes. In contrast, small bowel motility seemed normal in adult mice lacking DLX1 (Dlx1–/–). Even with detailed anatomic studies, we found no defects in ENS precursor migration, or neuronal and glial density in Dlx1/2–/– or Dlx1–/– mice. However, RNA sequencing of Dlx1/2–/– ENS revealed dysregulation of many genes, including vasoactive intestinal peptide (Vip). Using immunohistochemistry and reporter mice, we then found that Dlx1/2–/– mice have reduced VIP expression and fewer VIP-lineage neurons in their ENS. Our study reveals what we believe is a novel connection between Dlx genes and Vip and highlights the observation that dangerous bowel motility problems can occur in the absence of easily identifiable ENS structural defects. These findings may be relevant for disorders like chronic intestinal pseudo-obstruction (CIPO) syndrome.

Authors

Christina M. Wright, James P. Garifallou, Sabine Schneider, Heather L. Mentch, Deepika R. Kothakapa, Beth A. Maguire, Robert O. Heuckeroth

×

Figure 7

Vip levels are reduced in the developing ENS of Dlx1/2–/– mice at E14.5 and P0.

Options: View larger image (or click on image) Download as PowerPoint

Vip levels are reduced in the developing ENS of Dlx1/2–/– mice at E14.5...
(A) Bland-Altman plot of differentially expressed genes in Dlx1/2–/– versus WT E14.5 FACS-isolated small intestine (SI) ENCDCs after RNA-seq. (B) Heatmap of differentially expressed genes shows 20 dysregulated genes in Dlx1/2–/– ENS at E14.5, in addition to Dlx1 and Dlx2, which were substantially decreased in mutant mice. (C and D) Quantitative RT-PCR was performed for Vip (C) and Penk (D) mRNA on independent samples to validate expression patterns for these neurotransmitters in E14.5 mouse ENS (Vip, P = 0.0042, Student’s t test, n = 5 [+/+], n = 4 [–/–]; Penk, P = 0.0634, Student’s t test, n = 5 (+/+), n = 4 [–/–]). (E) Bland-Altman plot of differentially expressed genes in Dlx1/2–/– versus WT P0 FACS-isolated ENCDCs after RNA-seq. (F) Heatmap of differentially expressed genes shows 5 dysregulated genes in Dlx1/2–/– ENS at P0, in addition to Dlx1 and Dlx2. **P < 0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts